Every material Form 8-K Perspective Therapeutics, Inc. has filed with the SEC since October 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Perspective Therapeutics (CATX) filed an 8-K on November 6, 2026 with a press release and poster presenting updated interim results from its Phase 1/2a trial of [212Pb]lapemelanotide zapixetar (VMT01) in unresectable or metastatic melanoma, presented at the SITC 41st Annual Meeting in Phoenix. The filing reports antitumor activity at the 3.0 mCi dose and no dose-limiting toxicities across 20 patients, but the sample is small and the company says it is still evaluating dose optimization. The update is early-stage clinical data and contains no financial results or guidance.
Data cover 20 patients in three monotherapy cohorts as of the September 18, 2026 data cutoff; no dose-limiting toxicities were reported
At the 3.0 mCi dose, 2 of 8 patients had objective partial responses and the disease control rate was 75%
Grade 3 or higher treatment-emergent adverse events occurred in 5 of 20 patients (25%), none considered treatment-related
Perspective Therapeutics reported updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors, presented at the ESMO Congress 2026 on October 23, 2026. The company reported objective response rates of 33% in Cohort 2 and 50% in Cohort 3, with no dose-limiting toxicities and no discontinuations due to adverse events, and it aims to complete Phase 3 site start-up preparations around year-end 2026. The data are early and based on small cohorts, so the results may not hold as the trial continues.
Objective response rate was 33% (15 of 46) in Cohort 2 at 5.0 mCi and 50% (10 of 20) in Cohort 3 at 6.0 mCi, including unconfirmed responses
Progression-free survival was 72% at 18 months across all patients who received at least one treatment
20 of 68 patients (29%) had high-grade treatment-emergent adverse events, all Grade 3; no dose-limiting toxicities were reported
Phase 3 site start-up preparations targeted around year-end 2026, with Phase 3 initiation expected in 2027 following an End-of-Phase 2 meeting with the FDA
Perspective Therapeutics (NYSE American: CATX) announced on October 8, 2026 that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The filing says the designation is intended to facilitate development and expedite review, and that PSV359 is in an ongoing Phase 1/2a study, but it does not describe any financial effect.
FDA granted Fast Track Designation for PSV359 on or before October 8, 2026, per the press release dated October 8, 2026.
The designation covers adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study (NCT06710756).
The press release is filed as Exhibit 99.1; the filing reports no financial figures.
On October 1, 2026, Perspective Therapeutics updated its corporate presentation and filed it as Exhibit 99.1 to this Form 8-K. The filing contains no new financial results, guidance, or transaction terms, so it is an informational update rather than a change in the company's financial position.
Corporate presentation updated on October 1, 2026 and filed as Exhibit 99.1
Presentation covers three clinical-stage programs: VMT-α-NET, VMT01, and PSV359, plus CCK2R81
Filing states the programs have data in 2026 and references an ASCO 2026 data analysis
No financial figures, guidance, or transaction terms are disclosed in the 8-K text
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Perspective Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →